Article Versions Notes

Freire Boullosa L, Van Loenhout J, Hermans C, Lau HW, Merlin C, Marcq E, Takhsha FS, Martinet W, De Meyer GRY, Lardon F, et al. Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model. Pharmaceutics. 2022; 14(12):2761. https://doi.org/10.3390/pharmaceutics14122761

Freire Boullosa, Laurie, Jinthe Van Loenhout, Christophe Hermans, Ho Wa Lau, Céline Merlin, Elly Marcq, Farnaz Sedigheh Takhsha, Wim Martinet, Guido R. Y. De Meyer, Filip Lardon, and et al. 2022. "Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model" Pharmaceutics 14, no. 12: 2761. https://doi.org/10.3390/pharmaceutics14122761

Freire Boullosa, L., Van Loenhout, J., Hermans, C., Lau, H. W., Merlin, C., Marcq, E., Takhsha, F. S., Martinet, W., De Meyer, G. R. Y., Lardon, F., Smits, E. L. J., & Deben, C. (2022). Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model. Pharmaceutics, 14(12), 2761. https://doi.org/10.3390/pharmaceutics14122761